Literature DB >> 9371342

Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis.

I Lutsar1, A Ahmed, I R Friedland, M Trujillo, L Wubbel, K Olsen, G H McCracken.   

Abstract

Adequate concentrations of beta-lactam antibiotics in cerebrospinal fluid (CSF) are difficult to achieve for meningitis caused by drug-resistant Streptococcus pneumoniae. Ceftriaxone in dosages of 150 or 400 mg/kg of body weight per day, given in one or two doses, was used for the treatment of experimental highly cephalosporin-resistant (MIC and MBC, 4 microg/ml) pneumococcal meningitis. The bacterial killing rate (delta log10 CFU per milliliter per hour) and pharmacokinetic indices, including percentage of time the antibiotic concentration exceeded the MBC during a 24-h period (T>MBC), CSF peak concentration above the MBC, and area under the concentration-time curve from 0 to 24 h above MBC, were measured and correlated. By multiple stepwise regression, only T>MBC independently predicted the bacterial killing rate. There was a direct linear correlation between T>MBC in CSF and the bacterial killing rate during the first 24 h of therapy (r = 0.87; P = 0.004). Sterilization of CSF was achieved only when the T>MBC was 95 to 100%. In the first 24 h, the 200-mg/kg/12-h regimen, compared with the 400-mg/kg/24-h regimen, was associated with a greater T>MBC (87% +/- 10% versus 60% +/- 22%; P = 0.03) and greater bacterial killing rate (0.2 +/- 0.04 versus 0.13 +/- 0.07; P = 0.003), confirming that ceftriaxone exhibits time-dependent bactericidal activity. After 24 h, the T>MBC and the CSF sterilization rates were similar whether ceftriaxone was given once or twice daily.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371342      PMCID: PMC164137     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.

Authors:  J J Schentag; D E Nix; M H Adelman
Journal:  DICP       Date:  1991-10

2.  Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits.

Authors:  M G Täuber; S Kunz; O Zak; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

3.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

4.  High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins.

Authors:  P F Viladrich; C Cabellos; R Pallares; F Tubau; J Martínez-Lacasa; J Liñares; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Penicillin tolerance in multiply drug-resistant natural isolates of Streptococcus pneumoniae.

Authors:  H H Liu; A Tomasz
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

6.  The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits.

Authors:  M G Täuber; O Zak; W M Scheld; B Hengstler; M A Sande
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

7.  Ion-paired reversed-phase high-performance liquid chromatography assay for determination of ceftriaxone in human plasma and urine.

Authors:  G L Jungbluth; W J Jusko
Journal:  J Pharm Sci       Date:  1989-11       Impact factor: 3.534

8.  Penicillin resistance and defective lysis in clinical isolates of pneumococci: evidence for two kinds of antibiotic pressure operating in the clinical environment.

Authors:  P Moreillon; A Tomasz
Journal:  J Infect Dis       Date:  1988-06       Impact factor: 5.226

9.  Correlation of in vitro time-kill curves and kinetics of bacterial killing in cerebrospinal fluid during ceftriaxone therapy of experimental Escherichia coli meningitis.

Authors:  J M Decazes; J D Ernst; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

10.  Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.

Authors:  J E Leggett; B Fantin; S Ebert; K Totsuka; B Vogelman; W Calame; H Mattie; W A Craig
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

View more
  14 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

Review 2.  Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid.

Authors:  I Lutsar; I R Friedland
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 3.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Concentrations of cefpirome in cerebrospinal fluid of children with bacterial meningitis after a single intravenous dose.

Authors:  I R Friedland; E Sultan; K H Lehr; B Lenfant
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

Review 5.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

7.  Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci.

Authors:  Violeta Rodriguez-Cerrato; Cindy C McCoig; Jesus Saavedra; Tess Barton; Ian C Michelow; Robert D Hardy; Karen Bowlware; Janie Iglehart; Kathy Katz; George H McCracken
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 8.  Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

Authors:  R Nau; F Sörgel; H W Prange
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

9.  Daily variations in ceftriaxone pharmacokinetics in rats.

Authors:  M Rebuelto; L Ambros; M Rubio
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 10.  Management of meningitis due to antibiotic-resistant Acinetobacter species.

Authors:  Baek-Nam Kim; Anton Y Peleg; Thomas P Lodise; Jeffrey Lipman; Jian Li; Roger Nation; David L Paterson
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.